Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Apexigen
company
About
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $20M
- Industries
- Biopharma,Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2010
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult-to-treat diseases. They discover and develop innovative drugs that enhance tumor-specific immunity.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$20M
Apexigen has raised a total of
$20M
in funding over 2 rounds. Their latest funding was raised on
Aug 6, 2013 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 6, 2013 | Series A | $20M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Apexigen is funded by 2 investors.
WSR Capital
and Themes Investment Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Themes Investment Partners
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
